Esperion Reports Preliminary FY25 US Net Sales $156-$160mln, Up 35%-38% YoY.

• Esperion reports $156-$160M in preliminary FY25 U.S. net product sales, up 35-38% YoY • Total preliminary revenue of $400-$408M, a 20-23% increase compared to FY24 • Q4 retail prescription equivalents grew 34% YoY and 11.3% QoQ • Operating expenses expected to be between $210M and $245M for FY26 • Introduces Vision 2040 growth strategy, focusing on global growth of cardiometabolic franchise and expansion of pipeline into rare diseases.